CARB-X

Centauri Therapeutics has raised over $32.6 million in Series A financing to support the development of novel antibacterial candidates for difficult-to-treat infections, the company announced Wednesday. Investors in the round include Boehringer Ingelheim Venture Fund, Evotec and Novo Holdings REPAIR Impact Fund.

The London-based biotech won CARB-X backing in 2020 for its ABX01 dual-acting immunotherapy to treat serious infections caused by Gram-negative pathogens (including drug-…

Bugworks Research has secured $18 million in Series B financing, the biopharma announced Wednesday. The funds will support the clinical development of BWC0977, the India-based company’s novel broad-spectrum antibiotic against multidrug-resistant Gram-negative bacteria, among other projects.

Currently in Phase 1, BWC0977 has had CARB-X backing since 2017.

Promising C. difficile drug ridinilazole has failed in Phase 3, CARB-X grantee Summit Therapeutics announced Monday.

The Massachusetts-based company said the study showed that the investigational drug resulted in a higher observed Sustained Clinical Response rate than current standard-of-care vancomycin “but did not meet the study’s primary endpoint for superiority.”

The company did see a “meaningful reduction in recurrence,” however, which Summit Therapeutics linked to the…

Venatorx Pharmaceuticals announced Monday that it has entered into a licensing agreement with Roche to advance drug treatments for infections caused by carbapenem-resistant Enterobacterales (CRE) bacteria.

Boston University-led nonprofit CARB-X gave the Pennsylvania-based company $15 million between 2019 and 2020 to develop a new class of oral antibiotics to treat infections caused by multidrug-resistant N. gonorrhoeae.

Entasis Therapeutics’ investigational sulbactam-durlobactam (SUL-DUR) antibiotic was non-inferior versus standard colistin at preventing 28-day all-cause mortality in people with carbapenem-resistant A. baumannii infections, the Massachusetts-based biotech announced Monday, citing new Phase 3 data. The topline results also showed that SUL-DUR patients had higher clinical cure rates and lower rates of nephrotoxicity compared to those receiving the last-resort polymyxin-class antibiotic, per…

The Lancet Microbe published an article last week by European academics arguing that funding for antibiotic innovation remains “insufficient to address the scale of antibiotic resistance.” As an alternative, the authors proposed a “mission-oriented” antibiotic trials infrastructure to protect new drugs from commercial failure.

Through the so-called Networked Institute Model (NIM), a collection of public institutes would conduct all stages of antibiotic clinical trials, negotiate…

A therapy for the prevention of recurrent C. difficile infection (CDI) in high-risk patients has met the primary endpoint in a Phase 2 trial, Vedanta Biosciences announced Tuesday. The Massachusetts-based company’s VE303, an orally administered live biotherapeutic, yielded a 31.7% absolute risk reduction in rate of recurrence versus placebo, according to a press release.

Based on the Phase 2 data, the U.S. Biomedical Advanced Research and Development Authority (BARDA) exercised an…

A new nonprofit—dubbed the Incubator for Antibacterial Therapies in Europe (INCATE)—will support the European-based development of novel therapies, diagnostics and interventions to combat antimicrobial resistance. A Novo Holdings REPAIR Impact Fund director announced the incubator’s launch Sunday in a LinkedIn post.

INCATE’s support—a mix of consulting, business networking, and up to approximately $290,000 in non-dilutive funding (for selected projects)—aims to bring companies to “an…

Basilea Pharmaceutica announced Monday that the U.S. Biomedical Advanced Research and Development Authority has increased its total investment in the Swiss company’s ceftobiprole antibiotic candidate to $134.2 million.

The new tranche of $4.3 million will support a Phase 3 trial to evaluate the intravenous drug as an S. aureus bacteremia treatment, the press release said.

The Basel-based company won funding from CARB-X in May to develop a novel class of antibiotics against drug-…

Vaxcyte announced last week an additional $3.2 million CARB-X grant to support the company’s Investigational New Drug (IND) application for its novel universal Group A Streptococcus vaccine VAX-A1. CARB-X awarded the company $2.7 million for its initial funding period, per Vaxcyte’s press release.

Including future milestone payments, CARB-X’s VAX-A1 funding is worth up to $29.7 million to the California biotech.

Mentions: